2nd Department of Internal Medicine, Semmelweis University, Szentkirályi str 46, 1088, Budapest, Hungary.
MTA-SE Molecular Medicine Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.
Pathol Oncol Res. 2020 Oct;26(4):2209-2223. doi: 10.1007/s12253-020-00800-8. Epub 2020 Apr 20.
Up-regulation of the long non-coding RNA LINC00152 can contribute to cancer development, proliferation and invasion, including colorectal cancer, however, its mechanism of action in colorectal carcinogenesis and progression is only insufficiently understood. In this work we correlated LINC00152 expression with promoter DNA methylation changes in colorectal tissues along the normal-adenoma-carcinoma sequence and studied the effects of LINC00152 silencing on the cell cycle regulation and on the whole transcriptome in colon carcinoma cells using cell and molecular biology techniques. LINC00152 was significantly up-regulated in adenoma and colorectal cancer (p < 0.001) compared to normal samples, which was confirmed by real-time PCR and in situ hybridization. LINC00152 promoter hypomethylation detected in colorectal cancer (p < 0.01) was strongly correlated with increased LINC00152 expression (r=-0.90). Silencing of LINC00152 significantly suppressed cell growth, induced apoptosis and decreased cyclin D1 expression (p < 0.05). Whole transcriptome analysis of LINC00152-silenced cells revealed significant down-regulation of oncogenic and metastasis promoting genes (e.g. YES proto-oncogene 1, PORCN porcupine O-acyltransferase), and up-regulation of tumour suppressor genes (e.g. DKK1 dickkopf WNT signalling pathway inhibitor 1, PERP p53 apoptosis effector) (adjusted p < 0.05). Pathway analysis confirmed the LINC00152-related activation of oncogenic molecular pathways including those driven by PI3K/Akt, Ras, WNT, TP53, Notch and ErbB. Our results suggest that promoter hypomethylation related overexpression of LINC00152 can contribute to the pathogenesis of colorectal cancer by facilitating cell progression through the up-regulation of several oncogenic and metastasis promoting pathway elements.
长链非编码 RNA LINC00152 的上调可促进癌症的发展、增殖和侵袭,包括结直肠癌,但它在结直肠癌发生和进展中的作用机制尚不完全清楚。在这项工作中,我们将 LINC00152 的表达与沿正常-腺瘤-癌序列的结直肠组织中的启动子 DNA 甲基化变化相关联,并使用细胞和分子生物学技术研究 LINC00152 沉默对结肠癌细胞周期调节和整个转录组的影响。与正常样本相比,LINC00152 在腺瘤和结直肠癌中显著上调(p<0.001),这通过实时 PCR 和原位杂交得到了证实。在结直肠癌中检测到的 LINC00152 启动子低甲基化(p<0.01)与 LINC00152 表达的增加强烈相关(r=-0.90)。LINC00152 沉默显著抑制细胞生长,诱导细胞凋亡,并降低细胞周期蛋白 D1 的表达(p<0.05)。LINC00152 沉默细胞的全转录组分析显示,致癌和促进转移的基因显著下调(如 YES 原癌基因 1、PORCN 刺猬 O-酰基转移酶),肿瘤抑制基因上调(如 DKK1 dickkopf WNT 信号通路抑制剂 1、PERP p53 凋亡效应物)(调整后 p<0.05)。通路分析证实,LINC00152 相关的致癌分子通路的激活,包括由 PI3K/Akt、Ras、WNT、TP53、Notch 和 ErbB 驱动的通路。我们的结果表明,启动子低甲基化相关的 LINC00152 过表达可能通过上调多个致癌和促进转移的通路元件,促进细胞进展,从而促进结直肠癌的发病机制。